Amgen sued FDA for a 6-month reprieve from Sensipar generics—and lost

With Sensipar's patent expiration nearing—and $1.3 billion of its sales endangered by generic competition—Amgen is defending its blockbuster drug on multiple fronts. But the company recently came up short in an attempt to force the FDA to grant pediatric exclusivity and six extra months' protection.Original Article